Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct;7(3):e001746.
doi: 10.1136/rmdopen-2021-001746.

Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials

Kedar Gautambhai Mehta  1 , Tejas Patel  2 , Paragkumar D Chavda  3 , Parvati Patel  3
Affiliations
Comment

Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials

Kedar Gautambhai Mehta et al. RMD Open. 2021 Oct.

Abstract

Background: Colchicine, an anti-inflammatory drug is prescribed nowadays for COVID-19. In this meta-analysis, we evaluated efficacy and safety of colchicine in patients with COVID-19.

Methods: We searched databases for randomised controlled studies evaluating efficacy and/or safety of colchicine as compared with supportive care in patients with COVID-19. The efficacy outcomes were mortality, ventilatory support, intensive care unit (ICU) admission and length of hospital stay. The safety outcomes were adverse events, serious adverse events and diarrhoea. A meta-analytical summary was estimated using random effects model through Mantle-Hanzle method. An I2 test was used to assess heterogeneity. The Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach was used to assess quality of evidence for each outcome.

Results: Out of 69 full texts assessed, 6 studies (16148 patients with COVID-19) were included in meta-analysis. Patients receiving colchicine did not show significant reduction in mortality (risk difference, RD -0.00 (95% CI -0.01 to 0.01), I2=15%), ventilatory support (risk ratio, RR 0.67 (95% CI 0.38 to 1.21), I2=47%), ICU admission (RR 0.49 (95% CI 0.19 to 1.25), I2=34%), length of hospital stay (mean difference: -1.17 (95% CI -3.02 to 0.67), I2=77%) and serious adverse events (RD -0.01 (95% CI -0.02 to 0.00), I2=28%) than those who received supportive care only. Patients receiving colchicine had higher rates of adverse events (RR 1.58 (95% CI 1.07 to 2.33), I2=81%) and diarrhoea (RR 1.93 (95% CI 1.62 to 2.29), I2=0%) than supportive care treated patients. The GRADE quality of evidence was moderate for most outcomes.

Conclusion: The moderate quality evidence suggests no benefit of addition of colchicine to the standard care regimen in patients with COVID-19.

Keywords: COVID-19; anti-inflammatory agents; cytokines; non-steroidal.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
PRISMA flow diagram showing selection of studies. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Figure 2
Figure 2
Quality assessment of included studies as per risk of bias assessment tool - II.
Figure 3
Figure 3
Meta-analytical summary of efficacy outcomes. ICU, intensive care unit; IV, inverse variance; M-H, Mantel-Haenszel.
Figure 4
Figure 4
Meta-analytical summary of safety outcomes. M-H, Mantel-Haenszel.
See this image and copyright information in PMC

Comment on

References

    1. World Health Organisation . Coronavirus disease (COVID-19) situation reports, 2021. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situatio...
    1. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Immunol 2020;215:108427. 10.1016/j.clim.2020.108427 - DOI - PMC - PubMed
    1. WHO Solidarity Trial Consortium, Pan H, Peto R, et al. . Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med 2021;384:497–511. 10.1056/NEJMoa2023184 - DOI - PMC - PubMed
    1. RECOVERY Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (recovery): a randomised, controlled, open-label, platform trial. Lancet 2021;397:605–12. 10.1016/S0140-6736(21)00149-5 - DOI - PMC - PubMed
    1. RECOVERY Collaborative Group, Horby P, Mafham M, et al. . Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 2020;383:2030–40. 10.1056/NEJMoa2022926 - DOI - PMC - PubMed

Publication types